21 / 22
Page 57
J u l y 2 3 - 2 4 , 2 0 1 8 | R o m e , I t a l y
allied
academies
Joint Event on
Cardiology Congress 2018 & Microbe Infection 2018
Biomedical Research
|
ISSN: 0976-1683
|
Volume 29
2
nd
World Congress on
CARDIOLOGY
MICROBIOLOGY AND MICROBIAL INFECTION
&
39
th
Annual Congress on
Biomed Res 2018, Volume 29 | DOI: 10.4066/biomedicalresearch-C1-003
THE EFFICACY OF
GARCINIA MANGOSTANA
TO REDUCE ENDOTHELIAL
DYSFUNCTION AND DYSLIPIDEMIA IN HIGH FRAMINGHAM RISK SCORE
PATIENTS
Aditha Satria
1
, Djanggan Sargowo
1,3
, Ardian Rizal
1
, M Ryan Ramadhan
1
, Olivia Handayani
1
, Aris Munandar
1
,
Muhamad Rizki Fadlan
1,2
, Puspa Lestari
1
, Dion Setiawan
1
and
William Prayogo Susanto
1
1
Dr Saiful Anwar General Hospital, Indonesia
2
Brawijaya University, Indonesia
3
Center Study of Degeneratif Disease
Background:
Endothelial dysfunctionanddyslipidemiahavean important role in thedevelopment of atheroscleroticcardiovascular
disease.
Garcinia Mangostana
is an extract of mangosteen that has anti inflamation, immunomodulator, antioxidant, and anti lipid
effect. High level of inflamation, lipid profiles, oxidant markers, and circulating endothelial cell (CEC) with low level of endothelial
progenitor cell (EPC) predict poor outcomes of endothelial damage. This study was aimed to compare the efficacy of
Garcinia
Mangostana
to reduce endothelial dysfunction and dyslipidemia in high framingham risk score to be compare with placebo.
Parameters measured are inflamatory markers (IL-6, TNF α, HsCRP), CEC, EPC, and lipid profiles (total cholesterol, HDL, LDL, and
triglycerides).
Methods:
A randomized, single blind, placebo-controlled clinical trial was conducted in 90 high framingham risk score patients.
Study group consumes
Garcinia Mangostana
5x550 mg for three months as an additional therapy of their regular medications
and control group consumed placebo. The data was analyzed by paired t-test for parametric data and wilcoxon test for non
parametric data.
Results:
Post tests were performed after
Garcinia Mangostana
administration for three months. Inflamation parameters in study
group (IL-6, IL-1, and HsCRP) concentration was significantly decreased compared with placebo (−90.85±99.29, 3 pg/ml vs.
50.25±140, 52 pg/ml; P=0.000; −12.08±12, 1 pg/ml vs. 10.3±13.4 pg/ml; P=0.000; and −130.5±106, 3 pg/ml vs. -17.1±71, 7 pg/
ml; P=0.000). We also observed significance decrease in total cholesterol, LDL, and HbA1c (−12.52±37.31 mg/dl vs. 1.36±26.25
mg/dl; P=0.05; −18.29±28.6mg/dl vs. 1.8±18.5mg/dl; P=0.003; −0.29.±1.1 vs. 0.25±0.78; P=0.012; respectively) when compared
to placebo group. There was no difference in HDL, triglycerides and fasting blood glucose. CEC also significantly reduced with
increasing of EPC in study group (p=0.000).
Conclusion:
The result shows that
Garcinia Mangostana
extract has an efficacy to reduce inflamation (IL-1, IL-6, MDA, and
HsCRP), lipid profile, CEC and increase EPC level that reflects an improvement of endothelial function.
adithasatria@gmail.com